Fewer than one in five patients enrolled in the COAPT trial of the MitraClip (Abbott) were super-responders to their assigned therapies, with more seen in the percutaneous intervention group than in the medical control group. But understanding at the outset which patients will benefit most from the clip remains murky.
Writing in an early-online publication of the Journal of the American College of Cardiology, Paul A. Grayburn, MD (Baylor University Medical Center, Dallas, TX), and fellow COAPT investigators state that baseline predictors of being a super-responder in the trial included lower serum creatinine, low quality-of-life score, and treatment with the MitraClip itself.
This last finding, said Grayburn, drives home the point that the key to clinical improvement in functional mitral regurgitation (MR) is reducing that MR.
When we looked at MR grade and right ventricular systolic pressure at 30 days, they were a lot better in the super-responders compared to the nonresponders, which implies that the biggest predictor of being a super-responder is getting a successful MitraClip procedure that reduces your MR grade and reduces your RV systolic pressure, he told TCTMD.
COAPT Responders
As previously reported by TCTMD in 2018, COAPT was a randomized clinical trial of more than 600 patients with heart failure and severe functional MR showing that transcatheter mitral valve repair using the percutaneous clip on top of guideline-directed medical therapy (GDMT) significantly reduced not only the primary endpoint of heart failure (HF) rehospitalizations by 47%, but also mortality at 2 years, by 38%, as compared to people treated with GDMT only.It was at odds, however, with the French MITRA-FR trial of 304 patients, which found no benefit with the MitraClip in reducing death or HF hospitalizations.
In the wake of those two trials, there have been multiple efforts to explain the different outcomes as well as a push to figure out which patients would truly benefit from clip therapy on top of optimal medical care. This latest study, which was post hoc, attempted to get at answers to this question by stratifying patients as super-responders, responders, or nonresponders according to prospective definitions.
Super-responders were defined as patients alive at 12 months with no hospitalizations and an improvement in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) of 20 points or more. Responders were defined with the same clinical criteria and a KCCQ-OS improvement of 5-20 points, while nonresponders were those who had died, been hospitalized for heart failure, or saw their scores improve by less than 5.
Overall, after excluding 41 patients with missing KCCQ-OS scores, 27.2% of the trial participants in the MitraClip group were categorized as super-responders, 19% as responders, and 53.8% as nonresponders. By contrast, in the medical therapy arm, 10.2% were super-responders, 16.3% were responders, and 73.5% were nonresponders.
In multivariate analyses, the only three baseline predictors of super-response in the device arm were lower serum creatinine, low KCCQ-OS score, and MitraClip treatment. At 30 days, decreased MR severity as well as reduced RV systolic pressure were associated with better outcomes over the longer term.
That KCCQ-OS scores helped to predict a good response to therapy was not particularly surprising, Grayburn saidand has been hinted at in earlier analyses. That's expected because if you really feel bad, you could get better, so the people with the worst KCCQ scores have the greatest improvement, he said. And in a way that highlights the fact that if you're asymptomatic, it's hard to get better with the MitraClip. COAPT, he noted, did not enroll asymptomatic patients.
That assignment to the MitraClip device was such a strong predictor of being a super-responder reinforces whats known about the mechanism, Grayburn continued. He pointed to an analysis by COAPT investigator Saibal Kar, MDreported by TCTMD at EuroPCR last yearshowing that regardless of treatment assignment in the trial, having a lower residual MR at 30 days was strongly associated with reduced heart failure hospitalizations, all-cause mortality, and improved quality of life as compared to higher degrees of residual MR.
The fact that one in ten patients in the medical therapy group were super-responders also carries an important message, Grayburn said. We didn't really expect that, but I think it speaks to the fact that functional MR is dynamic and it can continue to respond to medical therapy over time. So even if we optimize medical therapy today and wait a month and then enrolled you in a trial, you can still get better 6 months or 1 year down the road.
And thats another key message from COAPT, he continued, especially for interventional cardiologists keen on using the clip: to be eligible for this trial, patients had to be truly symptomatic despite having maxed out on meds. What we're calling guideline-directed medical therapy requires uptitration of ACE inhibitors and ARBs or ARNI and beta-blockers to the highest doses that were successful in clinical trials of heart failure, said Grayburn.
A recent study from the CHAMP-HF registry showed that only 1% of the eligible heart failure population in the United States is getting all of their medications at the recommended doses, he noted, which is very, very sad because those drugs reduce your mortality 30%, and your heart failure, and they're not being used properly. So what we really need is for physicians to recognize that functional MR is a disease of the left ventricle and [that] properly and aggressively treating the left ventricular dysfunction will improve a lot of patients in terms of mortality and symptoms.
Still Work to Be Done
Commenting on the analysis for TCTMD, Alec Vahanian, MD (Hpital Bichat, Paris, France), who was on the steering committee for MITRA-FR, said it is very interesting and adds to the current knowledge.
Whats clear, he said in an email, is that predicting outcomes requires an understanding of both the patients global condition as well as the potential success of the intervention. Less obvious is how to identify responders more broadly, which is less catchy than super-responders, he noted. This is not clear today because of the discordant results of the two randomized controlled trials, so the discussion about what could be the definition of response to [GMDT] is also open. But I congratulate the COAPT investigators for looking closely at KCCQ, which is rather unique and necessary from a patient's perspective.
A quality-of-life score such as the KCCQ was not, unfortunately, part of MITRA-FR, Vahanian added, which will complicate efforts to combine the cohortsas proposed by Grayburn and colleaguesto help better identify patient-level characteristics that could help predict a response to therapy.
Rebecca Hahn, MD (NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY), who wrote an editorial accompanying the new paper, notes that given the very positive results for the MitraClip device in the COAPT trial, the results of this analysis seem a forgone conclusion. But the analysis does raise additional issues, she points out, including whether or not being a super-responder translates into meaningful outcomes down the road, and whether changes in right or left ventricle size in top responders in both groups translates into long-term benefit.
Hahn also points out that serum creatine (as well as KCCQ-OS) predicted super-response not only in patients randomized to MitraClip but also in those assigned to GDMT and as such might be a marker for patients in whom GDMT was not maximized due to concerns over renal function.
Finally, Hahn notes, the high nonresponder rate in both treatment groups (53.8% vs 73.5% for transcatheter mitral valve repair plus GDMT and GDMT, respectively) is surprising and deserves our attention.
A deeper look is warranted to determine how the pathoanatomy of MR, optimization of GDMT, and other factors play a role in responsiveness, she writes. Doing so may help clinicians make informed decisions regarding appropriate treatment options, understanding that both transcatheter devices and GDMT continue to improve.
Vahanian also zeroed in on the high proportion of patients who saw no benefit from the device. The relatively large percentage of nonresponders in the MitraClip arm after only 1 year suggests that there is a lot of work to be done to improve the efficacy of the strategy: earlier and better detection of MR/HF, better medical therapy before and after the procedure, and better interventions may be needed, he predicted, including newer devices or devices in combination.
Visit link:
Super-Responders in COAPT: Improving MR and QoL Is Key - TCTMD
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]